The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
A | Alimentary tract and metabolism | |
2
|
A16 | Other alimentary tract and metabolism products | |
3
|
A16A | Other alimentary tract and metabolism products | |
4
|
A16AB | Enzymes | |
5
|
A16AB29 |
| Active Ingredient |
|---|
|
Rebisufligene etisparvovec is an adeno-associated virus serotype 9 (AAV9)-based gene therapy designed to deliver a functional copy of the human N-sulfoglucosamine sulfohydrolase (SGSH) gene to cells. Intravenous infusion of rebisufligene etisparvovec results in production of the lysosomal enzyme sulfamidase in target tissues with subsequent breakdown of heparan sulfate (HS) in lysosomes. |
| Document | Type | Information Source | |
|---|---|---|---|
| FAYUVI Suspension for infusion | MPI, US: SPL/PLR | FDA, National Drug Code (US) |